Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
He served as President of the Kedah Tuberculosis Association, visiting Indian workers on rubber plantations to treat the disease, while she volunteered in the Kedah Family Planning Association. With the money from his medical practice, Mahathir indulged in his entrepreneurial streak and invested in property development, tin mining, a franchised petrol station, and a shop to do quick printing–sometimes to rescue Malay businessmen in trouble. He helped found the Malay Chamber of Commerce and served as its director.
== Sources == Crick, Francis (1990). What Mad Pursuit: a Personal View of Scientific Discovery (reprint ed.). New York: Basic Books. ISBN 0-465-09138-5. Maddox, Brenda (2002). Rosalind Franklin: the dark lady of DNA. London: HarperCollins. ISBN 0-06-018407-8. Olby, Robert (2009). Francis Crick: Hunter of Life's Secrets. Cold Spring Harbor Laboratory Press. ISBN 978-0-87969-798-3. Ridley, Matt (2006). Francis Crick: Discoverer of the Genetic Code. Ashland, OH: Atlas Books. ISBN 0-06-082333-X. Wilkins, Maurice (2003). The Third Man of the Double Helix: The Autobiography of Maurice Wilkins. Oxford University Press. ISBN 0-19-860665-6.
=== Proton transfer reaction chamber === Proton transfer reaction mass spectrometry has traditionally used drift tubes as ion traps. However, radio frequency ion funnels offer an attractive alternative, as they improve compound specific sensitivity significantly. This is due to increasing the effective reaction time and focusing the ions. The same pressure ranges are required for ion funnels and drift tubes, so the technology is not difficult to implement. Ion funnels have been shown to favor transmission of ions with high m/z.
Sources: en.wikipedia.org
=== Stool acidity test === This test can be used to diagnose lactose intolerance in infants, for whom other forms of testing are risky or impractical. The infant is given lactose to drink. If the individual is tolerant, the lactose is digested and absorbed in the small intestine; otherwise, it is not digested and absorbed, and it reaches the colon. The bacteria in the colon, mixed with the lactose, cause acidity in stools. Stools passed after the ingestion of the lactose are tested for level of acidity. If the stools are acidic, the infant is intolerant to lactose. Stool pH in lactose intolerance is less than 5.5.
=== New ownership === In December 2017, Patrick Cryne and his family sold an 80% stake in the club to NewCity Capital's Chien Lee and Pacific Media Group's Paul Conway. They were joined by Indian investor Neerav Parekh and Billy Beane, minority owner of and advisor for the Athletics, who was widely known for the Moneyball film portrayal, as part of an international investor consortium. Barnsley were relegated to the third tier in 2017–18. Following this, the new owners adopted a data-driven approach to identify talents, focusing on young players and team rebuilding. The club appointed Daniel Stendel as head coach, who introduced a high-pressing style of play. Barnsley were promoted back to the Championship the following season. In the 2019–20 season, under new coach Gerhard Struber, Barnsley avoided relegation from the Championship. In 2020–21, under the management of Valérien Ismaël, Barnsley finished fifth place and reached the EFL Championship Play-offs for the first time in 24 years, doing so with the youngest squad and one of the smallest budgets in the division. The Wall Street Journal called Barnsley a "Moneyball experiment". Prior to the 2021–22 season, Markus Schopp was appointed as the new head coach. In November 2021, he was dismissed after seven consecutive defeats. Three weeks later Poya Asbaghi was appointed as his successor. Fortunes improved little as Barnsley were relegated from the 2021–22 EFL Championship following a 2–1 defeat against Huddersfield Town. Asbaghi left the club by mutual consent shortly afterwards.
=== In cancer === Patients who are diagnosed with cancer, whether as outpatient undergoing treatment or hospitalized, are at a greater risk of malnutrition and cachexia. Cancer-related malnutrition can be attributed to the decrease in food intake, increase in the need for energy, and the alteration of metabolism. Patients should be assessed early on in their cancer treatment for any nutritional risk, such as by taking routine weights and BMI. Parenteral nutrition is indicated in cancer patients when it is not possible to access the digestive tract or if the tract is ineffective. In advanced cancer patients, the use of PN should be discussed in context of the risks and benefits, such as if the approximate survival rate is longer than 3 months and if PN would be expected to greatly improve the patients' quality of life. It is uncertain whether home parenteral nutrition improves survival or quality of life in people with malignant bowel obstruction.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.